$ANIP News

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules

ANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules 20, 30 And 60 Mg, Generic Version Of Reference Listed Drug Cymbalta

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?

ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting

Did FDA Approval of Generic Everolimus Suspension Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85

ANI Pharmaceuticals Receives Final FDA Approval Of Its Abbreviated New Drug Application For Everolimus Tablets For Oral Suspension

ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 Reasons to Like ANIP (and 1 Not So Much)

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript

ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results